Literature DB >> 29038270

Activity of Meropenem-Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in a Murine Model of Pyelonephritis.

William J Weiss1, Mark E Pulse2, Phung Nguyen2, Kelly Peterson2, Jessica Silva2, Jerry W Simecka2, David Valtierra2, Mojgan Sabet3, David C Griffith3.   

Abstract

The recently approved combination of meropenem and vaborbactam (Vabomere) is highly active against Gram-negative pathogens, especially Klebsiella pneumoniae carbapenemase (KPC)-producing, carbapenem-resistant Enterobacteriaceae We evaluated the efficacy of meropenem-vaborbactam against three clinically relevant isolates in a murine pyelonephritis model. The data indicate that the combination of meropenem and vaborbactam significantly increased bacterial killing compared to that with the untreated controls. These data suggest that this combination may have utility in the treatment of complicated urinary tract infections due to KPC-producing, carbapenem-resistant Enterobacteriaceae.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  KPC; Klebsiella pneumoniae carbapenemase; meropenem; pyelonephritis; vaborbactam

Mesh：

Substances：

Year:  2017        PMID： 29038270      PMCID： PMC5740365          DOI： 10.1128/AAC.01439-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  5 in total

1.  Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.

Authors:  Amabel Lapuebla; Marie Abdallah; Olawole Olafisoye; Christopher Cortes; Carl Urban; John Quale; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2015-06-01       Impact factor: 5.191

2.  Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.

Authors:  Scott J Hecker; K Raja Reddy; Maxim Totrov; Gavin C Hirst; Olga Lomovskaya; David C Griffith; Paula King; Ruslan Tsivkovski; Dongxu Sun; Mojgan Sabet; Ziad Tarazi; Matthew C Clifton; Kateri Atkins; Amy Raymond; Kristy T Potts; Jan Abendroth; Serge H Boyer; Jeffrey S Loutit; Elizabeth E Morgan; Stephanie Durso; Michael N Dudley
Journal:  J Med Chem       Date:  2015-03-17       Impact factor: 7.446

3.  Translational Efficacy of Humanized Exposures of Cefepime, Ertapenem, and Levofloxacin against Extended-Spectrum-β-Lactamase-Producing Escherichia coli in a Murine Model of Complicated Urinary Tract Infection.

Authors:  Marguerite L Monogue; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 4.  Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.

Authors:  L Silvia Munoz-Price; Laurent Poirel; Robert A Bonomo; Mitchell J Schwaber; George L Daikos; Martin Cormican; Giuseppe Cornaglia; Javier Garau; Marek Gniadkowski; Mary K Hayden; Karthikeyan Kumarasamy; David M Livermore; Juan J Maya; Patrice Nordmann; Jean B Patel; David L Paterson; Johann Pitout; Maria Virginia Villegas; Hui Wang; Neil Woodford; John P Quinn
Journal:  Lancet Infect Dis       Date:  2013-09       Impact factor: 25.071

5.  Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae.

Authors:  Mariana Castanheira; Paul R Rhomberg; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191
  5 in total
  8 in total

Review 1.  Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.

Authors:  Young R Lee; Nathaniel T Baker
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-04-19       Impact factor: 3.267

2.  Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model.

Authors:  Mojgan Sabet; Ziad Tarazi; David C Griffith
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 3.  New β-Lactam-β-Lactamase Inhibitor Combinations.

Authors:  Dafna Yahav; Christian G Giske; Alise Grāmatniece; Henrietta Abodakpi; Vincent H Tam; Leonard Leibovici
Journal:  Clin Microbiol Rev       Date:  2020-11-11       Impact factor: 26.132

Review 4.  Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 5.  Antibiotic resistance breakers: current approaches and future directions.

Authors:  Mark Laws; Ali Shaaban; Khondaker Miraz Rahman
Journal:  FEMS Microbiol Rev       Date:  2019-09-01       Impact factor: 16.408

Review 6.  The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections.

Authors:  Emilio Bouza
Journal:  J Antimicrob Chemother       Date:  2021-11-22       Impact factor: 5.790

7.  Vancomycin-arginine (STM-001) abrogates ESBL carrier and carbapenem-resistant Escherichia coli burden in a murine complicated urinary tract infection model.

Authors:  Lewis F Neville; Itamar Shalit; Peter A Warn; Jacob T Rendell
Journal:  J Antimicrob Chemother       Date:  2022-05-29       Impact factor: 5.758

Review 8.  The importance of pharmacokinetics and pharmacodynamics in antimicrobial drug development and their influence on the success of agents developed to combat resistant gram negative pathogens: A review.

Authors:  Mary E Palmer; Lauren J Andrews; Taylor C Abbey; Ashley E Dahlquist; Eric Wenzler
Journal:  Front Pharmacol       Date:  2022-07-25       Impact factor: 5.988
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.